abstract |
The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration; These compositions include a solubilizing agent, such as a modified β-cyclodextrin in an acidified solution, which may also include a chelating agent such as disodium edetate, EDTA; In clinical trials, a dose of the selected composition of 200 mg of posaconazole was found to achieve acceptable pharmacokinetic properties. |